as Libtayo, shrank tumors in a Phase 1 trial. Citing early results from its ongoing Phase 1 study designed to evaluate BHV-1510 as a single agent and in combination with cemiplimab in patients who ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ABI-007 is a novel formulation of paclitaxel, which incorporates nanoparticle technology to offer greater drug delivery to malignant cells, while reducing the need for premedications. Larotaxel is ...

In the trial, researchers are evaluating THIO with Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in more than 200 patients with locally advanced or metastatic NSCLC who have PD-L1 expression in 50 ...

Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM).